Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver
- PMID: 12451471
- DOI: 10.1007/s00280-002-0528-1
Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver
Abstract
Purpose: The enzymatic formation of 5-fluorouracil (5-FU) from two fluoropyrimidine prodrugs, doxifluridine (5'-DFUR) and tegafur (FT), was compared in vitro in order to determine whether there are differences between the metabolic profiles of the two prodrugs.
Methods: Conversion of the two fluoropyrimidine prodrugs to 5-FU was measured by high-performance liquid chromatography at a concentration of 500 micro M using the microsomal and cytosolic fractions of 12 human livers. The degree of correlation between the 5-FU-forming activities was determined using various cytochrome P450-dependent reactions.
Results: Liver microsomes catalyzed 5-FU formation from 5'-DFUR at rates of 10.0-160.1 pmol/min per mg protein and correlated well with CYP2A6-dependent coumarin 7-hydroxylase activity. The rates of microsomal 5-FU formation from FT ranged from 44.9 to 808.3 pmol/min per mg protein and also correlated with coumarin 7-hydroxylase activity. The cytosol fractions catalyzed 5-FU formation from 5'-DFUR at rates of 3,164.6 to 6,026.6 pmol/min per mg protein, almost two orders of magnitude higher than the rates of cytosolic 5-FU formation from FT (46.8-219.0 pmol/min per mg protein).
Conclusions: The cytosolic enzymes in livers appear to be important for 5-FU formation from 5'-DFUR. Both cytosolic and microsomal enzymes were involved almost equally in 5-FU formation from FT. The increased formation of 5-FU from 5'-DFUR might provide an answer to the question of why similar blood 5-FU levels were retained despite blood 5'-DFUR levels lower than blood FT levels.
Similar articles
-
Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.Drug Metab Dispos. 2000 Dec;28(12):1457-63. Drug Metab Dispos. 2000. PMID: 11095583
-
Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.Clin Cancer Res. 2000 Nov;6(11):4409-15. Clin Cancer Res. 2000. PMID: 11106261
-
Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.Clin Cancer Res. 2001 Mar;7(3):675-81. Clin Cancer Res. 2001. PMID: 11297264
-
Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.Drug Metab Dispos. 2004 Jul;32(7):762-7. doi: 10.1124/dmd.32.7.762. Drug Metab Dispos. 2004. PMID: 15205393
-
Fluoropyrimidine catabolism.Cancer Treat Res. 1995;78:71-93. doi: 10.1007/978-1-4615-2007-8_4. Cancer Treat Res. 1995. PMID: 8595148 Review. No abstract available.
Cited by
-
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.Br J Clin Pharmacol. 2012 May;73(5):776-85. doi: 10.1111/j.1365-2125.2011.04141.x. Br J Clin Pharmacol. 2012. PMID: 22486600 Free PMC article. Clinical Trial.
-
5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.World J Gastroenterol. 2005 Jul 7;11(25):3944-7. doi: 10.3748/wjg.v11.i25.3944. World J Gastroenterol. 2005. PMID: 15991299 Free PMC article.
-
N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.Cancer Chemother Pharmacol. 2010 May;66(1):11-9. doi: 10.1007/s00280-009-1128-0. Epub 2009 Sep 16. Cancer Chemother Pharmacol. 2010. PMID: 19756602 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources